Latest News for: serina

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Serina Therapeutics Inc)

Public Technologies 03 Feb 2026
Serina Therapeutics, Inc ... The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the ... Serina Therapeutics Inc.
Edit

From nutrition student to women’s health, a winding path finds purpose

The Bryan Eagle 02 Feb 2026
A science-based nutrition foundation and a willingness to pivot shaped Sydney Heck’s '21 path to maternal newborn nursingThe post From nutrition student to women’s health, a winding path finds purpose appeared first on AgriLife Today ....
Edit

Registration Statement - Specified Transactions (Form S-3) (Serina Therapeutics Inc)

Public Technologies 30 Jan 2026
... ("Legacy Serina"), pursuant to which Merger Sub merged with and into Legacy Serina, with Legacy Serina surviving the merger as a wholly owned subsidiary of AgeX (the "Merger").
Edit

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease (Serina Therapeutics Inc)

Public Technologies 29 Jan 2026
) Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease ... HUNTSVILLE, AL, Jan xx, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc ... About Serina Therapeutics.
Edit

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced ...

Nasdaq Globe Newswire 28 Jan 2026
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - ... .
Edit

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease (Form 8-K) (Serina Therapeutics Inc)

Public Technologies 28 Jan 2026
) Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease ... HUNTSVILLE, AL, January 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc ... About Serina Therapeutics.
Edit

Notice of Proposed Sale of Securities (Form 144) (Serina Therapeutics Inc)

Public Technologies 20 Jan 2026
). The text version of this document is not available ... Serina Therapeutics Inc.
Edit

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity (Form 8-K) (Serina Therapeutics Inc)

Public Technologies 15 Jan 2026
) Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity. - HUNTSVILLE, Jan 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American ... Serina Therapeutics Inc.
Edit

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Nasdaq Globe Newswire 15 Jan 2026
HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American ... .
Edit

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities (Serina Therapeutics Inc)

Public Technologies 06 Jan 2026
). CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc ... Hooven, Chairman and CEO of Enable Injections ... The use of the OBI for Sarclisa is currently under review by regulatory authorities ... About Enable Injections ... Serina Therapeutics Inc.
Edit

Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology (Serina Therapeutics Inc)

Public Technologies 18 Dec 2025
). CINCINNATI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc ... "Gaining SFDA authorization is a meaningful step for Enable," said Michael D. Hooven, Chairman and CEO of Enable Injections ... Media Contact. ... Source ... Serina Therapeutics Inc.
Edit

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Nasdaq Globe Newswire 11 Dec 2025
HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American ... .
Edit

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Nasdaq Globe Newswire 10 Dec 2025
– Company addresses FDA requests regarding formulation excipient. – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback ... .
Edit

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program (Form 8-K) (Serina Therapeutics Inc)

Public Technologies 10 Dec 2025
) Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program ... HUNTSVILLE, Dec 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American.
Edit

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nasdaq Globe Newswire 13 Nov 2025
13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American ... .

Article Search

tools
×
×
×
×